

1 **Community vaccination can shorten the COVID-19 isolation**
2 **period: an individual-based modeling approach**

3 **Chayanin Sararat¹, Jidchanok Wangkanai¹, Chaiwat Wilasang¹, Tanakorn**
4 **Chantanasaro¹, and Charin Modchang^{1,2,3*}**

5 ¹Biophysics Group, Department of Physics, Faculty of Science, Mahidol University, Bangkok 10400,
6 Thailand.

7 ²Centre of Excellence in Mathematics, MHESI, Bangkok 10400, Thailand.

8 ³ Thailand Center of Excellence in Physics, Ministry of Higher Education, Science, Research and
9 Innovation, 328 Si Ayutthaya Road, Bangkok 10400, Thailand.

10

11

12 * Corresponding author

13 E-mail: charin.mod@mahidol.edu

14

15

16

17

18

19

20

21

22

23

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 **Abstract**

25 **Background:** Isolation of infected individuals and quarantine of their contacts are usually
26 employed to mitigate the transmission of SARS-CoV-2. While 14-day isolation of infected
27 individuals could effectively reduce the risk of subsequent transmission, it also significantly
28 impacts the patient's financial, psychological, and emotional well-being. It is, therefore, vital
29 to investigate how the isolation duration could be shortened when effective vaccines are
30 available and in what circumstances we can live with COVID-19 without isolation and
31 quarantine.

32 **Methods:** An individual-based modeling approach was employed to estimate the likelihood of
33 secondary infections and the likelihood of an outbreak following the isolation of an index case
34 for a range of isolation periods. Our individual-based model integrates the viral loads and
35 infectiousness profiles of vaccinated and unvaccinated infected individuals. The effects of
36 waning vaccine-induced immunity against Delta and Omicron variant transmission were also
37 investigated.

38 **Results:** In the baseline scenario in which all individuals are unvaccinated, and no
39 nonpharmaceutical interventions are employed, there is a chance of about 3% that an
40 unvaccinated index case will make at least one secondary infection after being isolated for 14
41 days, and a sustained chain of transmission can occur with a chance of less than 1%. We found
42 that at the outbreak risk equivalent to that of 14-day isolation in the baseline scenario, the
43 isolation duration can be shortened to 7.33 days (95% CI 6.68-7.98) if 75% of people in the
44 community are fully vaccinated during the last three months. In the best-case scenario in which
45 all individuals in the community are fully vaccinated, isolation of infected individuals may no
46 longer be necessary. However, to keep the outbreak risk low, a booster vaccination may be
47 necessary three months after full vaccination. Finally, our simulations showed that the reduced
48 vaccine effectiveness against transmission of the Omicron variant does not much affect the risk
49 of an outbreak if the vaccine effectiveness against infection is maintained at a high level via
50 booster vaccination.

51 **Conclusions:** The isolation duration of a vaccine breakthrough infector could be safely
52 shortened if a majority of people in the community are immune to SARS-CoV-2 infection. A
53 booster vaccination may be necessary three months after full vaccination to keep the outbreak
54 risk low.

55

56 **Background**

57 SARS-CoV-2 spreads rapidly throughout the world, causing over 288.23 million
58 infections and 5.48 million deaths by the end of 2021 [1]. During the early phase of
59 transmission, when vaccines were unavailable, nonpharmaceutical interventions have been
60 frontline measures to mitigate the transmission [2, 3]. Isolation of infected individuals is a
61 critical strategy widely employed to break the transmission chain. Institution-based isolation
62 of confirmed cases has been shown in a modeling study to delay the epidemic's peak and reduce
63 the epidemic's size by approximately 57% [4]. Isolation, however, will be effective only if it
64 can be promptly employed to prevent pre-symptomatic and asymptomatic transmission [5]. In
65 addition, the isolation period should also be long enough to ensure that the infected individuals
66 do not spread the disease after the isolation. However, while prolonged isolation may reduce
67 the risk of transmission more effectively, it also significantly impacts the patient's financial,
68 psychological, and emotional well-being [6-8].

69 COVID-19 vaccines were first made available in the last of 2020 [9], and they have
70 been shown to be effective at preventing infection and transmission [10-12]. Despite the fact
71 that infections can occur even after being fully vaccinated, a faster viral clearance was observed
72 in the breakthrough infections, indicating that a breakthrough infected individual may have a
73 shorter duration of infectiousness [13, 14]. As a result, it suggests that those who have been
74 vaccinated may require a shorter period of isolation. It is vital to comprehend how the isolation
75 period could be reduced based on vaccine effectiveness, particularly when we desire to return
76 to normalcy and live with COVID-19 without quarantine and isolation measures.

77 In this study, we used an individual-based modeling approach to assess the likelihood
78 of secondary infections and the likelihood of an outbreak following isolation of a vaccinated
79 index case for a range of isolation periods. Our individual-based model accounts for
80 transmission heterogeneity, variation in the course of infection, and the disease's infectivity
81 profiles of both vaccinated and unvaccinated infected individuals. The effects of waning
82 vaccine-induced immunity and the delay in isolating infected individuals in the community
83 were also examined.

84

85 **Methods**

86 **Estimation of infectiousness profiles and vaccine efficiency against** 87 **transmission**


88 Individuals infected with SARS-CoV-2 can become infectious prior to the onset of
89 symptoms. In the case of unvaccinated individuals, the infectiousness peaks 2.1 days before
90 the onset of symptoms and then decreases gradually during the course of the illness [15].
91 Although the viral trajectories during the proliferation stage are similar in both unvaccinated
92 and vaccinated individuals, the viral loads are cleared faster in vaccine breakthrough infections
93 than in the unvaccinated individuals [13, 14]. The disease infectiousness (F) prior to the peak
94 of both vaccinated and unvaccinated infectors was therefore assumed to follow a gamma
95 distribution, as described in [15]. After the peak period, data on C_t values collected in Singapore
96 [13] were used to determine the infectiousness profile. The infectiousness was considered to
97 be directly proportional to the viral load (V) that exceeds a threshold of 10^6 copies, i.e.,
98 $F \propto V \times 10^{-6}$ [16]. C_t values were converted to viral load (V) using the procedures outlined in
99 [14]. Because of the faster viral clearance time, the disease transmissibility of vaccinated
100 infectors could be averted compared to unvaccinated ones. In this work, we estimated the
101 vaccine efficacy against transmission from a percentage of reduction in the area under the
102 curves of the disease infectiousness profiles of vaccinated and unvaccinated infectors.

103

104 **Model structure**

105 In order to examine the probability of post-isolation infections, the transmissions of the
106 COVID-19 were simulated with individuals categorized as susceptible (S), latent (L), infectious
107 (I), recovered (R), isolated (Q), and fully vaccinated (V) according to their infection and
108 vaccination status. Infectious individuals are further divided into symptomatic (I_S) and
109 asymptomatic (I_A) infectious individuals, with the assumption that asymptomatic infectious
110 individuals are less infectious than symptomatic ones. Although COVID-19 vaccines cannot
111 entirely protect people against infection, they are still beneficial in decreasing the chance of
112 infection. In addition, even when vaccinated individuals get infected, they will be less likely to
113 transmit the disease to other individuals. In our model, vaccine breakthrough infections are
114 distinguished from infections in susceptible individuals by subscripts V and S , as shown in

115 **Figure 1(A)**. After being infected, individuals enter a latent state before becoming infectious.
 116 Finally, infectious individuals move either to recovered or isolated compartments.



117

118 **Figure 1: Model structure of the COVID-19 transmission.** (A) Schematic of the
 119 compartmental model showing progressive of the disease and transition of individuals across
 120 different compartments. (B) Example of the expected number of secondary cases made by a
 121 single primary case drawn from a negative binomial distribution. (C) An illustration of
 122 transmission events due to the primary case (red circle). The generation time is a time duration
 123 between a primary case's infection and one of its subsequent secondary cases. The incubation
 124 period is a time duration from exposure to symptom onset. The inset shows the infectiousness
 125 profiles of unvaccinated (UV) and vaccinated (V) infected individuals.

126

127 The number of secondary infections caused by a single primary case, Z , for each
128 infected individual is estimated from a negative binomial distribution with a mean equal to the
129 reproduction number (R_0) and dispersion parameter (k) (**Figure 1(B)**). Because of the lower
130 infectivity of asymptomatic infectious individuals, they contribute fewer infections; the mean
131 number of secondary cases made by an asymptomatic infectious individual was reduced by a
132 factor r . For the vaccine breakthrough infectors, the mean of the distribution is also reduced
133 due to the efficiency against transmission of vaccines (e_I).

134 An example of the transmission events is illustrated in **Figure 1(C)**. The incubation
135 period, time from exposure to symptom onset, is assumed to follow the Gamma distribution
136 with a mean of 5.8 days [15]. The time of each new infection is drawn from a random number
137 distribution that is distributed according to the infectiousness profile of the infectors. As a result
138 of the vaccine's effectiveness against infection, vaccinated individuals are less likely to become
139 infected. The effective infectious period is determined by whether or not infected individuals
140 are isolated. If infected individuals are isolated, they will be contagious until they are isolated.
141 Although transmission can be prevented during isolation, post-isolation infections are still
142 possible. The generation time between infection of a primary case and one of its subsequent
143 secondary cases is dependent on both the incubation period and the infection time. In our study,
144 the primary index case is assumed to be isolated immediately after becoming infected, whereas
145 other subsequent infected individuals in the community are isolated with a default time delay
146 of 6.8 days.

147

148 **Estimating the probability of secondary transmission and the probability of** 149 **a successful outbreak after isolation**

150 The probability of secondary transmission was defined as a chance that a primary case
151 makes at least one subsequence infection after the isolation. The probability of a successful
152 outbreak was estimated from the likelihood that the chain of transmission initiated from the
153 index case after isolation continues for more than 90 days. We have checked that the threshold
154 value of 90 days can distinguish between simulations in which the disease goes extinct and
155 simulations in which the disease spreads substantially until reaching the equilibrium state. The

156 probabilities were estimated using three batches of simulations, each containing 1,000
157 realizations.

158

159 **Table 1: Model parameters and their default values**

Parameter	Default value	Source
Basic reproduction number (R_0)	5.08	[17]
Overdispersion parameter (k)	0.08	[18]
Incubation period distribution (Gamma distribution)		
- Mean	5.8 days	
- Shape parameter	3.64	[15]
- Scale parameter	1.59	
Probability of being symptomatic		
- Unvaccinated individuals	0.573	[19]
- Vaccinated individuals	0.431	[19]
Reduction in infectiousness of asymptomatic individual (r)	0.58	[20]
Vaccine effectiveness against infection (e_S)	0.79	[12]
Vaccine effectiveness against transmission (e_I)	0.25	Estimation
Probability that symptomatic individuals will be isolated	0.8	Assumption
Probability that asymptomatic individuals will be isolated	0.1	Assumption
Time delay from infection to isolation		
- Index case	0 days	Assumption
- Infected individuals in community	6.8 days	Assumption

160

161 Results

162 Impact of vaccination on post-isolation transmission


163 We explored the probability of a primary infected individual making at least one
164 secondary infection and the probability of a successful outbreak, i.e., having a sustained chain
165 of transmission, after being released from isolation. In the baseline scenario in which the
166 primary case and all other individuals in the community are unvaccinated, we found that there
167 is a chance of about 3% that the unvaccinated index case will make at least one secondary
168 infection after being isolated for 14 days, and a sustained chain of transmission can occur with
169 a chance of less than 1% (left bars in **Figure 2(A)-(B)**). However, if the index case has already
170 been vaccinated, we found that although all other individuals in the community are
171 unvaccinated, only about 10 days of isolation is equivalent to 14-day isolation of unvaccinated
172 index case (red lines and red symbols in **Figure 2**).

173 Vaccinating people in the community can further reduce the likelihood of secondary
174 infections and the probability of a successful outbreak. It was found that higher community
175 vaccine coverages decrease the chance of secondary transmission following the isolation of the
176 vaccinated index case more, especially when the isolation periods are short. In addition, when
177 the isolation period is longer than 12 days, there is no apparent difference between different
178 vaccination coverages. At the outbreak risk equivalent to that of 14-day isolation in the baseline
179 scenario, the isolation duration of the primary vaccinated infector can be shortened to 9.33 days
180 (95% CI 8.68-9.98) if 50% of people in the community are vaccinated (**Figure 2 (D)**). When
181 75% of people in the community are vaccinated, the isolation period can be further shortened
182 to 7.33 days (95% CI 6.68-7.98). Finally, we found that in the best-case scenario in which all
183 individuals are vaccinated, although post-isolation infections are still possible for the isolation
184 period of shorter than 6 days, the chance of sustained chain of transmission to occur is
185 extremely rare. In this case, isolation of infected individuals may no longer be necessary.

186

187

188



189

190 **Figure 2: Impacts of isolating a primary vaccinated infector on post-isolation**
 191 **transmission.** Probability of secondary transmission (A) and probability of a successful
 192 outbreak in which a chain of transmission can be sustained (C) after a range of isolation periods
 193 and vaccination levels in the community. The corresponding probabilities in the baseline
 194 scenario where the index case and all other individuals in the community are unvaccinated are
 195 shown as bar graphs on the left side of both subfigures. (B) and (D) show the isolation period
 196 equivalent to the 14-day isolation period in the baseline scenarios, regarding the probability of
 197 secondary transmission and the probability of a successful outbreak, respectively. Error bars
 198 indicate 95% CI.

199

200

201

202

203 **Effect of waning vaccine-induced immunity**

204 As the vaccine effectiveness against Delta variant infection decreases over time [21],
205 we evaluated its effect on the probability of secondary infections and the probability of a
206 successful outbreak following isolation. We found that for a low level of immunization (< 25%
207 coverage), both the post-isolation transmission probability and the successful outbreak
208 probability are not significantly affected by the waning of vaccine effectiveness (**Figure 3 (A)**
209 **and (D)**). However, for higher vaccine coverage, the effect of the decline in the vaccine
210 effectiveness is more pronounced, especially when the isolation durations are short. Note,
211 however, that although at high vaccination coverage (> 75% coverage), there is a more
212 significant effect of immunity waning across a range of isolation periods, the probability of an
213 outbreak is still lower than that in the case when 25% of the population are vaccinated. With
214 the vaccine coverage of 75%, for example, after four months of vaccination, the outbreak risk
215 climbs from 0.9% to 4.2% for 3-day isolation and increases from 1.3% to 7.7% for no isolation
216 (**Figure 3 (E)**). When all individuals in the community are vaccinated, despite a substantial
217 decrease in vaccine effectiveness after four months, the chance of a successful outbreak is still
218 lower than 4% even there is no isolation (**Figure 3 (F)**).


219 We also investigated how the change in vaccine effectiveness against transmission
220 would influence the likelihood of secondary infections and the probability of a successful
221 outbreak. In this part, we considered the vaccine effectiveness against transmission (e_t) ranges
222 from 0% to 40%, and the vaccine effectiveness against infection (e_s) of 90% and 50%,
223 corresponding to the effectiveness against infection of Delta variant after being fully vaccinated
224 with two doses of mRNA BNT162b2 vaccine for one month and four months, respectively.
225 We found that during the first four months after complete vaccination, when the vaccine
226 effectiveness against infection is high, the vaccine effectiveness against transmission had only
227 a minor effect on the transmission, especially when the isolation period is long (**Figure 4**).

228

229

230

231



232

233 **Figure 3: The effect of reduction in vaccine effectiveness against SARS-CoV-2 infection.**

234 The time evolution of the probability of at least one secondary infection (A-C) and probability

235 of a successful outbreak (D-F) following the release of a breakthrough infector from isolation

236 as the vaccine effectiveness against infection wanes (black lines, right y-axis). Data of vaccine

237 effectiveness against infection were obtained from reference [21].

238

239

240

241


242

243

244

245

246



247


248 **Figure 4: The influence of vaccine effectiveness against SARS-CoV-2 transmission.** The
249 probability of at least one secondary infection ((A) and (B)) and a successful outbreak ((C) and
250 (D)) after being released from isolation into a community with a vaccination level of 75%. The
251 vaccine effectiveness against transmission (e_i) was varied from 0% to 40%, and the vaccine
252 effectiveness against infection (e_s) was fixed at 90% (left column) and 50% (right column).

253

254 Impact of community case-isolation and other control measures

255 We next evaluated the impact of time delay from infection to the isolation of infected
256 individuals in the community on the spread of SARS-CoV-2. Our results indicated that the
257 outbreak would be less likely to occur if case isolation is performed with a shorter delay
258 (Figure 5). For example, under the vaccine coverage of 75%, the outbreak risk could be
259 suppressed to lower than 1% if the isolation can be performed within 3 days after infections.
260 To maintain the same level of an outbreak risk, a longer duration of the isolation is needed for
261 the isolation with longer delays. For instance, for a 5-day delay, at least 5 days of isolation may
262 be required, and for a 7-day delay, at least 7 days of isolation may be needed. When only 25%
263 of individuals are vaccinated, isolation may be required for at least 10 days, regardless of how
264 quickly infected individuals are isolated.

265



266


267 **Figure 5: Impact of time delay from infection to isolation under vaccination coverages**
268 **of (A) 25% and (B) 75%.**

269

270

271

272 The effective reproduction number (R) is commonly used to measure the disease
273 transmissivity under different control measures. To consider the effects of other control
274 measures, a sensitivity analysis on the effective reproduction number has been performed. In
275 combination with other non-pharmaceutical interventions, we found that community
276 vaccination could further shorten the isolation period (**Figure 6**). For instance, in the absence
277 of any non-pharmaceutical interventions and the vaccine coverage is only 25%, case isolation
278 may be required for at least 12 days to reduce the outbreak risk to below 1%. However, if other
279 control measures are concurrently implemented at a level that could reduce the effective
280 reproduction number to 3.2, only one week of isolation is sufficient. Importantly, in this case,
281 isolation will be no longer necessary if the community vaccination level reaches 75%.
282



283

284 **Figure 6: A sensitivity analysis on the effective reproduction number.** The probability of a
285 successful outbreak under the community vaccination coverages of (A) 25% and (B) 75%.

286

287

288

289

290

291 Discussion

292 In this work, we evaluated the likelihood of at least one secondary infection and the
293 likelihood of an outbreak following the isolation of a vaccine breakthrough infector for a
294 specified period of time. Our modeling results indicated that vaccines play a critical role in
295 reducing the likelihood of post-isolation transmission. We discovered that the duration of
296 isolation for an infected individual who has already been vaccinated could be reduced as
297 opposed to the 14-day duration of isolation for unvaccinated individuals. Additionally, the
298 duration of isolation can be reduced further if the majority of the community members are
299 immune to the disease (**Figure 2**).

300 In the best-case scenario in which all individuals in the community are fully vaccinated
301 with two doses of mRNA BNT162b2 vaccine, isolation of Delta-variant breakthrough infected
302 individuals may no longer be required, at least during the first three months after being fully
303 vaccinated, if no other non-pharmaceutical interventions are implemented. After three months,
304 however, as the vaccine effectiveness against infection drops to around 60% [21], the
305 probability of post-isolation transmission increases rapidly after this time, especially in the
306 cases of short isolation periods. This result indicates that booster vaccination may be needed
307 after being fully vaccinated for three months; otherwise, more extended isolation periods or
308 other non-pharmaceutical control measures may be necessary to compensate for the increased
309 transmission risk (**Figure 3**).

310 With a faster viral clearance time in vaccinated individuals, vaccines have been
311 hypothesized to reduce onward transmission from infected vaccinated individuals. According
312 to our estimations, the vaccine effectiveness against transmission of 24.6% is comparable to
313 the effectiveness against transmission with the Delta variant after getting two doses of the
314 Pfizer vaccine [22]. However, the emergence of the Omicron variant has raised serious
315 concerns about its capability to evade vaccine protection. After receiving two doses of mRNA
316 vaccines, the vaccine effectiveness in preventing Omicron-variant transmission drops to less
317 than 5% [22]. Nevertheless, our simulations showed that the reduced vaccine effectiveness
318 against Omicron-variant transmission does not much affect the risk of secondary infection if
319 the vaccine effectiveness against infection is restored to a high level via booster vaccination
320 [23] (**Figure 4**). However, since at the time of writing this manuscript, the data on the waning
321 of vaccine effectiveness against Omicron-variant infections were not available, we assumed
322 that they wane at the same rate as the Delta variant.

323 When considering the effect of delay in isolation of infected individuals in the
324 community, we found that a shorter delay to isolation can further shorten the isolation period,
325 especially in the high vaccine coverage settings. In addition, we found that while an outbreak
326 may still occur in the absence of isolation in the community with low vaccination coverage,
327 the risk could be minimized when additional control measures such as contact tracing and
328 quarantine of their contacts, as well as testing, are implemented (**Figures 5 and 6**).

329

330

331 **Funding**

332 The research is financially supported by the National Research Council of Thailand, the
333 Thailand Center of Excellence in Physics (ThEP), the Centre of Excellence in Mathematics,
334 the Center of Excellence on Medical Biotechnology (CEMB), the Science, Research and
335 Innovation Promotion and Utilization Division, the Office of the Permanent Secretary Ministry
336 of Higher Education, Science and Innovation, Thailand. Chayanin Sararat is supported by the
337 Science Achievement Scholarship of Thailand (SAST).

338

339 **Author contributions**

340 CM conceived and designed the study. CS, JW, CW, and TC conducted the study. CS and CM
341 analysed the results. CS and CM wrote the manuscript.

342

343

344

345

346

347

348 References

- 349 1. Hannah Ritchie, E.M., Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban
350 Ortiz-Ospina, Joe Hasell, Bobbie Macdonald, Diana Beltekian and Max Roser,
351 *Coronavirus Pandemic (COVID-19)*. Our World in Data, 2020.
- 352 2. Wilasang, C., et al., *Reduction in effective reproduction number of COVID-19 is higher*
353 *in countries employing active case detection with prompt isolation*. Journal of travel
354 medicine, 2020. **27**(5): p. taaa095.
- 355 3. Wilasang, C., et al., *Reconstruction of the transmission dynamics of the first COVID-*
356 *19 epidemic wave in Thailand*. Scientific Reports, 2022. **12**(1): p. 2002.
- 357 4. Dickens, B.L., et al., *Institutional, not home-based, isolation could contain the COVID-*
358 *19 outbreak*. The Lancet, 2020. **395**(10236): p. 1541-1542.
- 359 5. Moghadas, S.M., et al., *The implications of silent transmission for the control of*
360 *COVID-19 outbreaks*. Proceedings of the National Academy of Sciences, 2020.
361 **117**(30): p. 17513-17515.
- 362 6. Pietrabissa, G. and S.G. Simpson, *Psychological Consequences of Social Isolation*
363 *During COVID-19 Outbreak*. Frontiers in Psychology, 2020. **11**(2201).
- 364 7. Jain, A., et al., *Impact on mental health by "Living in Isolation and Quarantine" during*
365 *COVID-19 pandemic*. Journal of family medicine and primary care, 2020. **9**(10): p.
366 5415-5418.
- 367 8. Hossain, M.M., A. Sultana, and N. Purohit, *Mental health outcomes of quarantine and*
368 *isolation for infection prevention: a systematic umbrella review of the global evidence*.
369 *Epidemiology and health*, 2020. **42**: p. e2020038-e2020038.
- 370 9. Baraniuk, C., *Covid-19: How the UK vaccine rollout delivered success, so far*. *bmj*,
371 2021. **372**.
- 372 10. Lopez Bernal, J., et al., *Effectiveness of Covid-19 vaccines against the B. 1.617. 2*
373 *(Delta) variant*. *N Engl J Med*, 2021: p. 585-594.

- 374 11. Harris, R.J., et al., *Effect of Vaccination on Household Transmission of SARS-CoV-2 in*
375 *England*. New England Journal of Medicine, 2021. **385**(8): p. 759-760.
- 376 12. Sheikh, A., et al., *SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital*
377 *admission, and vaccine effectiveness*. The Lancet, 2021. **397**(10293): p. 2461-2462.
- 378 13. Chia, P.Y., et al., *Virological and serological kinetics of SARS-CoV-2 Delta variant*
379 *vaccine-breakthrough infections: a multi-center cohort study*. medRxiv, 2021: p.
380 2021.07.28.21261295.
- 381 14. Kissler, S.M., et al., *Viral dynamics of SARS-CoV-2 variants in vaccinated and*
382 *unvaccinated individuals*. medRxiv, 2021: p. 2021.02.16.21251535.
- 383 15. Kang, M., et al., *Transmission dynamics and epidemiological characteristics of Delta*
384 *variant infections in China*. medRxiv, 2021: p. 2021.08.12.21261991.
- 385 16. Larremore, D.B., et al., *Test sensitivity is secondary to frequency and turnaround time*
386 *for COVID-19 screening*. Science advances, 2021. **7**(1): p. eabd5393.
- 387 17. Liu, Y. and J. Rocklöv, *The reproductive number of the Delta variant of SARS-CoV-2*
388 *is far higher compared to the ancestral SARS-CoV-2 virus*. Journal of Travel Medicine,
389 2021. **28**(7).
- 390 18. Endo, A., et al., *Estimating the overdispersion in COVID-19 transmission using*
391 *outbreak sizes outside China [version 3; peer review: 2 approved]*. Wellcome Open
392 Research, 2020. **5**(67).
- 393 19. Tang, L., et al., *Asymptomatic and Symptomatic SARS-CoV-2 Infections After*
394 *BNT162b2 Vaccination in a Routinely Screened Workforce*. JAMA, 2021. **325**(24): p.
395 2500-2502.
- 396 20. Byambasuren, O., et al., *Estimating the extent of asymptomatic COVID-19 and its*
397 *potential for community transmission: systematic review and meta-analysis*. Official
398 Journal of the Association of Medical Microbiology and Infectious Disease Canada,
399 2020. **5**(4): p. 223-234.

- 400 21. Tartof, S.Y., et al., *Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6*
401 *months in a large integrated health system in the USA: a retrospective cohort study.*
402 The Lancet, 2021. **398**(10309): p. 1407-1416.
- 403 22. Gardner, B.J. and A.M. Kilpatrick, *Estimates of reduced vaccine effectiveness against*
404 *hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-*
405 *2 variant, Omicron (B.1.1.529), using neutralizing antibody titers.* medRxiv, 2021: p.
406 2021.12.10.21267594.
- 407 23. Andrews, N., et al., *Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1.*
408 *529) variant of concern.* MedRxiv, 2021.
- 409